Browse

IS DUODENAL INVASION A RELEVANT PROGNOSTICATOR IN PATIENTS UNDERGOING ADJUVANT CHEMORADIOTHERAPY FOR DISTAL COMMON BILE DUCT CANCER?

DC Field Value Language
dc.contributor.authorKim, Kyubo-
dc.contributor.authorChie, Eui Kyu-
dc.contributor.authorJang, Jin-Young-
dc.contributor.authorKim, Sun Whe-
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorHa, Sung W.-
dc.contributor.authorKim, Tae-You-
dc.contributor.authorOh, Do-Youn-
dc.date.accessioned2012-05-25T06:41:02Z-
dc.date.available2012-05-25T06:41:02Z-
dc.date.issued2010-07-15-
dc.identifier.citationINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS; Vol.77 4; 1186-1190ko_KR
dc.identifier.issn0360-3016-
dc.identifier.urihttps://hdl.handle.net/10371/76479-
dc.description.abstractPurpose: To analyze the outcome of adjuvant chemoradiotherapy for patients with distal common bile duct (CBD) cancer who underwent curative surgery, and to identify the prognostic factors for these patients. Methods and Materials: Between January 1991 and December 2002,38 patients with adenocarcinoma of the distal CBD underwent curative resection followed by adjuvant chemoradiotherapy. There were 27 men and 11 women, and the median age was 60 years (range, 34-73). Adjuvant radiotherapy was delivered to the tumor bed and regional lymph nodes up to 40 Gy at 2 Gy/fraction with a 2-week planned rest. Intravenous 5-fluorouracil (500mg/m(2)/day) was given on day 1 to day 3 of each split course. The median follow-up period was 39 months. Results: The 5-year overall survival rate of all patients was 49.1%. On univariate analysis, only histologic differentiation (p = 0.0005) was associated with overall survival. Tumor size (<= 2cm vs. > 2cm) had a marginally significant impact on the treatment outcome (p = 0.0624). However, there was no difference in overall survival rates between T3 and T4 tumors (p = 0.6189), for which the main determinants were pancreatic and duodenal invasion, respectively. On multivariate analysis, histologic differentiation (p = 0.0092) and tumor size (p = 0.0046) were independent risk factors for overall survival. Conclusions: Long-term survival can be expected in patients with distal CBD cancer undergoing curative surgery and adjuvant chemoradiotherapy. Histologic differentiation and tumor size were significant prognostic factors predicting overall survival, whereas duodenal invasion was not. This finding suggests the need for further refinement in tumor staging. (C) 2010 Elsevier Inc.ko_KR
dc.language.isoenko_KR
dc.publisherELSEVIER SCIENCE INCko_KR
dc.subjectDistal common bile duct cancerko_KR
dc.subjectAdjuvant chemoradiotherapyko_KR
dc.subjectDuodenal invasionko_KR
dc.titleIS DUODENAL INVASION A RELEVANT PROGNOSTICATOR IN PATIENTS UNDERGOING ADJUVANT CHEMORADIOTHERAPY FOR DISTAL COMMON BILE DUCT CANCER?ko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김규보-
dc.contributor.AlternativeAuthor지의규-
dc.contributor.AlternativeAuthor장진영-
dc.contributor.AlternativeAuthor김선희-
dc.contributor.AlternativeAuthor오도윤-
dc.contributor.AlternativeAuthor임석아-
dc.contributor.AlternativeAuthor김태유-
dc.contributor.AlternativeAuthor방영주-
dc.contributor.AlternativeAuthor하성환-
dc.identifier.doi10.1016/j.ijrobp.2009.06.033-
dc.citation.journaltitleINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS-
dc.description.citedreferenceNelson JW, 2009, INT J RADIAT ONCOL, V73, P148, DOI 10.1016/j.ijrobp.2008.07.008-
dc.description.citedreferenceEbata T, 2007, WORLD J SURG, V31, P2008, DOI 10.1007/s00268-007-9173-5-
dc.description.citedreferenceHughes MA, 2007, INT J RADIAT ONCOL, V68, P178, DOI 10.1016/j.ijrobp.2006.11.048-
dc.description.citedreferenceBen-David MA, 2006, INT J RADIAT ONCOL, V66, P772, DOI 10.1016/j.ijrobp.2006.05.061-
dc.description.citedreferencede Castro SMM, 2004, J GASTROINTEST SURG, V8, P775, DOI 10.1016/j.gassur.2004.08.006-
dc.description.citedreferenceHeron DE, 2003, AM J CLIN ONCOL-CANC, V26, P422-
dc.description.citedreferenceKim S, 2002, INT J RADIAT ONCOL, V54, P414-
dc.description.citedreferenceYoshida T, 2002, ARCH SURG-CHICAGO, V137, P69-
dc.description.citedreference*AJCC, 2002, AJCC CANC STAG MAN, P107-
dc.description.citedreferenceSerafini FM, 2001, AM SURGEON, V67, P839-
dc.description.citedreferenceYeo CJ, 1998, ANN SURG, V227, P821-
dc.description.citedreferenceHejna M, 1998, EUR J CANCER, V34, P977-
dc.description.citedreferenceZerbi A, 1998, DIGEST SURG, V15, P410-
dc.description.citedreferenceFong Y, 1996, BRIT J SURG, V83, P1712-
dc.description.citedreferenceNakeeb A, 1996, ANN SURG, V224, P463-
dc.description.citedreferenceKamada T, 1996, INT J RADIAT ONCOL, V34, P767-
dc.description.citedreferenceCOX JD, 1995, INT J RADIAT ONCOL, V31, P1341-
dc.description.citedreferenceMILLER AB, 1981, CANCER, V47, P207-
dc.description.citedreferenceKAPLAN EL, 1958, JAMA-J AM MED ASSOC, V457, P481-
dc.description.tc0-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse